Geron Corp (GERN) concluded trading on Thursday at a closing price of $3.98, with 6.36 million shares of worth about $25.32 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.31% during that period and on December 05, 2024 the price saw a loss of about -0.50%. Currently the company’s common shares owned by public are about 603.10M shares, out of which, 564.54M shares are available for trading.
Stock saw a price change of -4.56% in past 5 days and over the past one month there was a price change of -5.69%. Year-to-date (YTD), GERN shares are showing a performance of 88.63% which increased to 113.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.64 but also hit the highest price of $5.34 during that period. The average intraday trading volume for Geron Corp shares is 8.14 million. The stock is currently trading -0.43% below its 20-day simple moving average (SMA20), while that difference is down -3.67% for SMA50 and it goes to 0.09% higher than SMA200.
Geron Corp (NASDAQ: GERN) currently have 603.10M outstanding shares and institutions hold larger chunk of about 78.66% of that.
The stock has a current market capitalization of $2.41B and its 3Y-monthly beta is at 0.52. It has posted earnings per share of -$0.32 in the same period. It has Quick Ratio of 2.74 while making debt-to-equity ratio of 0.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GERN, volatility over the week remained 3.44% while standing at 4.63% over the month.
Stock’s fiscal year EPS is expected to rise by 18.17% while it is estimated to increase by 73.37% in next year. EPS is likely to grow at an annualized rate of 5.00% for next 5-years, compared to annual growth of -16.08% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on November 05, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it. On September 09, 2024, Leerink Partners Initiated their recommendations, while on April 30, 2024, Robert W. Baird Downgrade their ratings for the stock with a price target of $4.50. Stock get a Buy rating from TD Cowen on April 29, 2024.
